Thrombosis News and Research

Latest Thrombosis News and Research

Six-month results from BIOTRONIK's PRO-Kinetic Energy stent study presented at TCT 2011

BIOTRONIK AG announced that the six-month results of the ENERGY Registry were presented last week by Prof. Raimund Erbel at the Transcatheter Cardiovascular Therapeutics (TCT 2011) conference.

14 Nov 2011

Accumetrics VerifyNow test shows patients with high PRU exhibit higher stent thrombosis

Accumetrics, Inc., developer of the VerifyNow System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, today announced that patients with high platelet reactivity, i.e. high PRU values as measured by the Accumetrics VerifyNow P2Y12 Test, exhibited an approximately four times higher rate of stent thrombosis than patients without high platelet reactivity, as seen in the ADAPT-DES registry.

10 Nov 2011

Merck's NEXPLANON 68 mg now available in the U.S.

Merck today announced that NEXPLANON (etonogestrel implant) 68 mg, a long-acting, progestin-only single-rod hormonal contraceptive, is now available in the United States.

10 Nov 2011

Boston Scientific reports positive long-term data from PERSEUS clinical program

Boston Scientific Corporation reports positive long-term data from the PERSEUS clinical program, which demonstrated favorable two-year safety and effectiveness outcomes for the ION (TAXUS Element) Paclitaxel-Eluting Platinum Chromium Stent System versus prior-generation paclitaxel-eluting stents.

9 Nov 2011

Patient and nurse safety may be related by common causes

A safe working environment for nurses is also a safe environment for the patients in their care, according to a new study led by public health researchers at Drexel University. Researchers, led by Dr. Jennifer Taylor, an assistant professor in Drexel's School of Public Health, found that safety climate was associated with both patient and nurse injuries, suggesting that patient and nurse safety may be linked outcomes.

8 Nov 2011

InfraReDx TVC Imaging System to be exhibited at TCT 2011

InfraReDx, Inc., a medical device company committed to advancing the diagnosis and management of coronary artery and other vascular diseases, today announced that its TVC Imaging System for the true vessel characterization of coronary artery disease will be highlighted during the annual Transcatheter Cardiovascular Therapeutics Meeting (TCT 2011).

7 Nov 2011

Dual imaging approach could improve diagnosis, treatment of coronary artery disease

A new device that combines two microimaging technologies can reveal both the detailed anatomy of arterial linings and biological activities that, in coronary arteries, could indicate the risk of heart attacks or the formation of clots in arterial stents.

7 Nov 2011

Doctors may stop anti-TNF medications for RA patients before surgery to reduce disease flares

As guidelines recommend, doctors appear to be stopping anti-TNF medications before surgery, but may be doing so far sooner than is necessary, according to a new study by researchers at Hospital for Special Surgery. These medications are used to treat a variety of inflammatory diseases, including rheumatoid arthritis, and better timing of withdrawal prior to surgery might minimize the risk of disease flares.

6 Nov 2011

Medtronic highlights scientific sessions of interest on program for TCT 2011

Offering the broadest range of medical technology for the interventional and surgical treatment of cardiovascular disease, Medtronic, Inc. today highlighted scientific sessions of interest on the program for TCT 2011, which takes place Nov. 7-11 in San Francisco.

From Medtronic 5 Nov 2011

Janssen receives FDA approval for Xarelto to prevent stroke in people with AF

The U.S. Food and Drug Administration today approved the anti-clotting drug Xarelto (rivaroxaban) to reduce the risk of stroke in people who have abnormal heart rhythm.

5 Nov 2011

AHA/ASA honors UH Case Medical Center with Get With The Guidelines-Stroke award

For the third consecutive year, University Hospitals (UH) Case Medical Center has received the American Heart Association/American Stroke Association's Get With The Guidelines--Stroke Gold Plus Quality Achievement Award.

4 Nov 2011

DJO Global third quarter net sales increase 12.7% to $263.1 million

DJO Global, Inc., a leading global provider of medical device solutions for musculoskeletal health, vascular health and pain management, today announced financial results for its operating subsidiary, DJO Finance LLC, for the third quarter of fiscal 2011, ended October 1, 2011.

2 Nov 2011

FDA approves Abbott's XIENCE PRIME Everolimus Eluting Coronary Stent System

Abbott today announced it has received U.S. Food and Drug Administration (FDA) approval for the next-generation XIENCE PRIME Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease.

2 Nov 2011

Oral hormonal contraceptives linked to blood clots: Study

A new study has shown that women who use new type of contraceptive pills are twice as likely to develop life threatening blood clots as those who take older versions. Oral hormonal contraceptives have been known to increase the risk of a blood clot in deep leg veins, known as venous thromboembolism (VTE). These can prove fatal if they travel to the lungs. But, researchers at the University of Copenhagen, Denmark, found the “third-generation” pills are doubly harmful than the older versions.

30 Oct 2011

Massachusetts court awards injunction preventing Watson from selling Amphastar's generic LOVENOX

Watson Pharmaceuticals, Inc., today confirmed that the United States District Court for the District of Massachusetts has granted Momenta Pharmaceuticals, Inc. and Sandoz Inc.'s request for a preliminary injunction preventing Watson and Amphastar Pharmaceuticals, Inc. from marketing or selling Amphastar's Enoxaparin Sodium Injection, a generic equivalent to Sanofi-aventis' LOVENOX.

29 Oct 2011

Researchers announce new method to build important heparin drug

Robert Linhardt is working to forever change the way some of the most widely used drugs in the world are manufactured. Today, in the journal Science, he and his partner in the research, Jian Liu, have announced an important step toward making this a reality. The discovery appears in the October 28, 2011 edition of the journal Science in a paper titled "chemoenzymatic synthesis of homogeneous ultra-low molecular weight heparins."

28 Oct 2011

Biogen Idec enters global collaboration for oral Syk inhibitor program with Portola

Biogen Idec and Portola Pharmaceuticals, Inc. today announced that they have entered into an exclusive, worldwide collaboration and license agreement under which both companies will develop and commercialize highly selective, novel oral Syk inhibitors for the treatment of various autoimmune and inflammatory diseases, including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).

28 Oct 2011

Enoxaparin can reduce risk of VTE in plastic surgery patients

For plastic surgery patients at high risk, treatment with the anticoagulant (blood-thinning) drug enoxaparin can reduce the risk of serious blood clot-related complications called venous thromboembolism (VTE), reports a study in the November issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons.

28 Oct 2011

Clinical and genetic risk factors associated with early stent thrombosis

Patients with certain genes or specific factors related to use of the anti-clotting drug clopidogrel are more likely to experience a blood clot within a coronary stent shortly after placement, according to a study in the October 26 issue of JAMA.

27 Oct 2011

Study provides details on genetics behind many metabolic diseases

In what is so far the largest investigation of its kind, researchers uncovered a wide range of new insights about common diseases and how they are affected by differences between two persons' genes. The results from this study could lead to highly targeted, individualized therapies.

27 Oct 2011